Fig 2: (A) Western blot analysis of RhoA expression in VSMCs. (B) Immunofluorescence microscopy of SRF localization and expression (red; nuclei are stained blue with DAPI) (magnification, ×200). (C) Western blot analysis of SRF expression in VSMCs, 1, Control group; 2, lentivirus-NELIN-small interfering RNA-VSMC group; 3, NELIN-VSMC group. *P<0.05 versus control group. VSMC, vascular smooth muscle cell; SRF, serum response factor; RhoA, Ras homolog gene family member A.

Fig 3: Morphology of VSMCs, (A) control group; (B) lentivirus-NELIN-small interfering RNA-VSMC group; (C) NELIN-VSMC group. Magnification, ×200. VSMC, vascular smooth muscle cell.

Fig 4: Western blot analysis of SRF and a-SM-actin expression in VSMCs affected by Y-27632. (A) Western blot analysis of SRF expression in VSMCs following treatment with Y-27632. (B) Relative density of SRF expression under different conditions. (C) Western blot analysis of a-SM-actin expression in VSMCs following treatment with Y-27632. (D) Relative density of a-SM-actin in different groups. 1. NELIN-VSMC group 2. Y-27632 group. *P<0.05 versus NELIN-VSMC group. VSMC, vascular smooth muscle cell; SRF, serum response factor; SM, smooth muscle.

Fig 5: NELIN expression in VSMCs analyzed by western blot. 1, Control group; 2, lentivirus-NELIN-small interfering RNA-VSMC group; 3, NELIN-VSMC group. *P<0.05 versus control group. VSMC, vascular smooth muscle cell.